References of "Belgian Journal of Hematology"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailVaccination guidelines in hematopoietic transplant patients : recommendations from the BHS Transplant Committee
Moors, I.; Callens, S.; BEGUIN, Yves ULg et al

in Belgian Journal of Hematology (in press)

Over the past years, hematopoietic stem cell transplantation (HSCT) is increasingly used as a consolidation therapy in several haematological diseases and solid tumours. In the post-transplantation period ... [more ▼]

Over the past years, hematopoietic stem cell transplantation (HSCT) is increasingly used as a consolidation therapy in several haematological diseases and solid tumours. In the post-transplantation period, the immunity of HSCT recipients is impaired due to toxicity of the pre-HSCT treatment (chemo- and/or radiotherapy) and the conditioning regimen with reset of the immune system and – in case of allogeneic stem cell transplantation – possible graft-versus-host-disease (GVHD) and use of immunosuppressive drugs. This leads to a considerably increased risk of infections, with higher morbidity and mortality in these patients. Therefore, prevention of infections, through antibiotic prophylaxis, life style adjustments, germfree nutrition and revaccination, is of major importance to improve outcomes. In this article we present the Belgian guidelines for vaccination after hematopoietic stem cell transplantation, based on available data in the literature and international guidelines, taking into account the availability of vaccines and - if applicable - their reimbursement in Belgium. We present a general vaccination schedule for post-HSCT patients, a proposition for pre-transplant vaccination and donor vaccination, and an overview of special indications such as travel vaccinations and vaccinations of close contacts and health care workers, with guidelines for titer follow up. [less ▲]

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailGalectin expression in the multiple myeloma microenvironment
Muller, Joséphine ULg; CAERS, Jo ULg; Binsfeld, Marilène ULg et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailHemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency.
SID, Sélim ULg; Dugauquier, D.; DE PRIJCK, Bernard ULg et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 18 (1 ULg)
Full Text
See detailMultiple myeloma cells instruct myeloid-derived suppressor cells to release pro-angiogenic cytokines
Binsfeld, Marilène ULg; Heusschen, Roy ULg; Lamour, Virginie et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 12 (2 ULg)
Full Text
See detailEstablishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
Binsfeld, Marilène ULg; BEGUIN, Yves ULg; Belle, Ludovic et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailSummary of the BVAC/ABCA program hosted by the general annual meeting of the BHS in Ghent, Friday January 25th 2013.
KORNREICH, A; GOTHOT, André ULg

in Belgian Journal of Hematology (2013), 4(2), 77-82

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailErythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial.
JASPERS, Aurélie ULg; Baron, Frédéric ULg; WILLEMS, Evelyne ULg et al

in Belgian Journal of Hematology (2013, January)

Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO ... [more ▼]

Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO) therapy was very efficient when started one month after transplantation. We also demonstrated that anemia after nonmyeloabalative (NM) HCT was less sensitive to rhEPO therapy than after conventional allogeneic HCT. This prompted us to confirm these findings in a prospective randomised trial. One hundred and thirty-one patients were randomised (1:1) between no treatment (arm 1) or erythropoietin (Neorecormon) at the dose of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been attained, the dose of rhEPO was reduced by half, while it was withheld when Hb was = 14g/dL. Cohort A included 42 patients on day 28 after myeloablative HCT, cohort B 39 patients on day 28 after NMHCT, and cohort C 50 patients on day 0 of NMHCT. Primary endpoints included proportion of complete correctors (i.e. patients reaching Hb = 13g/dL) and median time to achieve Hb correction in each arm. The proportion of complete correctors before day 126 posttransplant was 0% in group 1A vs 52.4% in group 2A, 0% in group 1B vs 69.5% in group 2B and 19.1% in group 1C vs 70.2% in group 2C. Median time to achieve Hb = 13g/dL was not reached in group 1B vs 49 days in group 2B; 363 and 59 days in groups 1A and 1B respectively and 363 and 87 days in groups 3A and 3B respectively (figure 1). Hb evolution in each group is shown in figure 2. Seventyone patients (47/62 in control groups and 24/57 in treated groups, p=0.0003) required red blood cell transfusions. The difference was most pronounced in cohort B. There was no difference in rates of thrombo-embolic events or other complications between the two arms. In conclusion, this is the first trial to demonstrate that EPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT. [less ▲]

Detailed reference viewed: 27 (11 ULg)
Full Text
Peer Reviewed
See detailPrimary immune thrombocytopenia in adults
Janssens, A.; Lambert, C.; Bries, G. et al

in Belgian Journal of Hematology (2013), 4(1), 2-11

The Belgian Hematological Society (BHS) guideline panel on adult primary immune thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to make recommendations on the best ... [more ▼]

The Belgian Hematological Society (BHS) guideline panel on adult primary immune thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to make recommendations on the best strategies for frontline and subsequent-line treatment. No treatment is necessary for patients with platelet counts higher than 30000/ l in the absence of bleeding symptoms. Patients newly diagnosed or relapsing after a long-term treatment-free period can be managed with corticosteroids with or without intravenous immunoglobulins. A second line therapy is indicated for those patients who are intolerant or unresponsive to or relapse after initial corticosteroid treatment and have a risk of bleeding. The guideline panel recommends splenectomy as it is the treatment with the highest curative potential and an acceptable safety pro le. If possible, splenectomy should be delayed to at least twelve months after diagnosis as spontaneous remission can occur in this time period. Thrombopoietin receptor (TPO-R) agonists are recommended for patients who are refractory to or relapse after splenectomy or who have a contra-indication to splenectomy irrespective of the duration of ITP. The guideline panel agrees that rituximab, azathioprine, cyclophosphamide, cyclosporine A, danazol, dapsone, mycophenolate mofetil and vincristine/vinblastine are potential treatment options, especially for patients refractory to TPO-R agonists. [less ▲]

Detailed reference viewed: 31 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS).
Van Obbergh, F.; Van Hoof, A.; Verhoef, G. et al

in Belgian Journal of Hematology (2013), 4 (3)

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each ... [more ▼]

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist's expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted stratégies. [less ▲]

Detailed reference viewed: 30 (5 ULg)
Full Text
See detailInfusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease
Hannon, Muriel ULg; Lechanteur, C.; Somja, Joan ULg et al

in Belgian Journal of Hematology (2013), Abstracts book(Supplement of 28th General Meeting of the Belgian Hematological Society), 15

Detailed reference viewed: 14 (7 ULg)
Full Text
See detailThe Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution
Binsfeld, Marilène ULg; Otjacques, Eléonore ULg; Hannon, Muriel ULg et al

in Belgian Journal of Hematology (2013), Abstracts book(Supplement of 28th General Meeting of the Belgian Hematological Society), 41

Detailed reference viewed: 20 (12 ULg)
Full Text
See detailComparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning
Hannon, Muriel ULg; Humblet-Baron, S.; Graux, C. et al

in Belgian Journal of Hematology (2013), Abstracts book(Supplement of 28th General Meeting of the Belgian Hematological Society), 38

Detailed reference viewed: 11 (6 ULg)
Full Text
Peer Reviewed
See detailGuidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL
Verhoef, G.; Schroyens, W.; Bron, D. et al

in Belgian Journal of Hematology (2013), 4 (2)

Detailed reference viewed: 31 (1 ULg)
Full Text
See detailAdaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation
Binsfeld, Marilène ULg; Belle, Ludovic ULg; Hannon, Muriel ULg et al

in Belgian Journal of Hematology (2012), Abstracts book(Supplement of 27th General Meeting of the Belgian Hematological Society), 16

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailLess vasoocclusive disease after intravenous ersus oral busulfan for autologous hematopoietic cell transplantation : the Belgian pediatric experience
Huybrechts, S.; BEGUIN, Yves ULg; Ferster, A. et al

in Belgian Journal of Hematology (2012), 3(2), 34-40

Busulfan is commonly used in preparative conditioning regimens prior to hematopoietic stem cell transplantation in children and young adults for malignant and non-malignant disorders. For many years ... [more ▼]

Busulfan is commonly used in preparative conditioning regimens prior to hematopoietic stem cell transplantation in children and young adults for malignant and non-malignant disorders. For many years Busulfan was only available in an oral form, resulting in large inter- and intra-patients variability in plasma exposure, associated with higher graft failure rate as well as higher toxicity such as venoocclusive disease. With the development of an intravenous formulation of Busulfan, a more accurate control of both the inter- and intra-patient variability has been provided. The goal of this study was to evaluate the use and efficacy of intravenous Busulfan in comparison with the oral formulation in children undergoing an autologous transplantation after conditioning with Busulfan. Despite the small number of patients, this study confirmed the apparent benefit of intravenous Busulfan in children undergoing an autologous HSCT. The use of a 5-level dose schedule defined by body weight resulted in an efficient engraftment with marked reduction in the incidence of veno-occlusive disease compared with oral Bu. In terms of diseasefree outcome, survival and event-free survival, similar results have been obtained in both groups. The choice of this formulation of Busulfan should therefore be considered. [less ▲]

Detailed reference viewed: 38 (1 ULg)
Full Text
Peer Reviewed
See detailAcademic clinical trials run by the transplant committee of the Belgian Hematological Society
VANDAMME, Arnaud ULg; Schots, Rik; BEGUIN, Yves ULg

in Belgian Journal of Hematology (2012), 3(2), 62-67

The Transplantation Committee of the Belgian Hematological Society (BHS) is supported by all university centers and nonuniversity centers with significant transplant activity. The committee is involved in ... [more ▼]

The Transplantation Committee of the Belgian Hematological Society (BHS) is supported by all university centers and nonuniversity centers with significant transplant activity. The committee is involved in the development of transplant guidelines and recommendations, the transplant peer review process, contacts with regulatory authorities, the introduction of expanded access and medical need programs and the initiation of academic studies addressing important questions in the transplant field. Since 2008, 8 clinical trials have been initiated after approval by the Ethics Committees and the National Competent Authority (AFMPS/FAGG). So far, one of them has been completed and is being prepared for publication. In this paper, we briefly describe the rationale, objectives, treatment arms, major inclusion criteria and current status of these different trials. In addition and for each trial a link is provided to the BHS website to obtain more details regarding inclusion criteria, participating centers and administrative/contact information [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
See detailEvidence for Expansion of Host-derived CMV-specific CD8+ T cells after Allogeneic Transplantation with Non-Myeloablative Conditioning
MENTEN, Catherine ULg; Castermans, E.; Hannon, Muriel ULg et al

in Belgian Journal of Hematology (2012), Abstracts book(Supplement of 27th General Meeting of the Belgian Hematological Society), 16

Detailed reference viewed: 4 (1 ULg)
Full Text
See detailRapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice
Belle, Ludovic ULg; Binsfeld, Marilène ULg; DUBOIS, Sophie ULg et al

in Belgian Journal of Hematology (2012), Abstracts book(Supplement of 27th General Meeting of the Belgian Hematological Society), 14

Detailed reference viewed: 9 (6 ULg)